Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study

  • PDF / 353,482 Bytes
  • 6 Pages / 595.276 x 790.866 pts Page_size
  • 96 Downloads / 168 Views

DOWNLOAD

REPORT


ORIGINAL ARTICLE

Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study Francesco Minisola1 Cristiana Cipriani2 Luciano Colangelo2 Mirella Cilli2 Alessandro Sciarra1 Magnus Von Heland1 Luciano Nieddu3 Emanuela Anastasi4 Roberto Pascone5 Valeria Fassino Daniele Diacinti6 Flavia Longo6 Salvatore Minisola2 Jessica Pepe2 ●

























Received: 6 March 2017 / Accepted: 9 June 2017 © Springer Science+Business Media, LLC 2017

Abstract Purpose Prostate cancer is the most common tumor in men. To the best of our knowledge a systematic assessment of bone and mineral abnormalities has not been performed in prostatic cancer patients consecutively enrolled. Methods This study was therefore carried out to investigate changes of skeletal and mineral metabolism in patients with prostate cancer (n = 69). A population of patients with cancer of various origin was also investigated as a control group (n = 53), since a comparison with non-prostate cancer patients has not been previously reported. Results In the prostatic cancer group, one patient had extremely high values of C-terminal Fibroblast Growth Factor 23, low values of tubular reabsorption of phosphate and very high values of bone alkaline phosphatase, suggesting the diagnosis of oncogenic osteomalacia. We found nine patients with primary hyperparathyroidism in the group Francesco Minisola and Cristiana Cipriani contributed equally to this work. * Salvatore Minisola [email protected] 1

Department of Gynecology-Obstetrics & Urology, Sapienza University of Rome, Rome, Italy

2

Department of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy

3

Faculty of Economics, UNINT University, Via delle Sette Chiese 139, 00147 Rome, Italy

of prostate cancer vs. only one in cancer patients group (p < 0.026). We stratified the population on the basis of Gleason score, prostate specific antigen and hormonal therapy. Using a generalized linear model with a logit link to predict the probability of developing primary hyperparathyroidism, only Gleason score, C-terminal fibroblast growth factor 23 and hormonal therapy had a significant effect (p < 0.05). Controlling for other covariates, a rise in fibroblast growth factor 23 increases the odds of developing primary hyperparathyroidism by 2% (p = 0.017), while patients with higher values of Gleason score have a much greater probability of developing primary hyperparathyroidism (log-odds = 3.6, p < 0.01). The probability decreases with higher values of Gleason score while on hormonal therapy; a further decrease was observed in patients on hormonal treatment and lower values of GS. Finally, lower grade of Gleason score without hormonal therapy have a significant protective factor (p < 0.01) decreasing the odds of developing primary hyperparathyroidism by 8%. Conclusion We showed a remarkable prevalence of primary hyperparathyroidism in men with prostate cancer; the multivariate analysis demonstrates that higher aggressiveness of pros